Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 5 Stomach Neoplasms 2 Small Cell Lung Carcinoma 2 Ovarian Neoplasms 2 Uterine Cervical Neoplasms 1 Solid Neoplasms 1 SCLC 1 Prostatic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Metastatic Solid Tumors 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Glioblastoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Advanced Solid Tumors 1

Interventions

Temozolomide 94 Radiotherapy 40 Bevacizumab 40 Lomustine 21 Radiation 18 Surgical Procedures, Operative 10 Carboplatin 9 pembrolizumab 8 Nivolumab 8 Carmustine 8 Irinotecan 7 IL13-PE38 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 Flucytosine 6 Cyclophosphamide 6 ABT-414 6 vocimagene amiretrorepvec 5 depatuxizumab mafodotin 5 Valacyclovir 5 Drug Therapy 5 veledimex 4 sargramostim 4 enzastaurin 4 NVP-BKM120 4 Gemcitabine 4 Dianhydrogalactitol 4 Chlorotoxin 4 Aminolevulinic Acid 4 verubulin 3 selinexor 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Glioblastoma × Platinum × Clear all

NCT07138001 2025-08-22

Phase 2 Clinical Trial of KH617

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Phase 2 Not yet recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡